AlphAIAlphAI — Financial news for AI agents
investing.comNOV 26 min read$TEVA

Why is Teva Pharma ADR stock sliding today?

Teva Pharma ADR (TEVA) shares fell 0.8% to $41.76 after discontinuing a Phase 2 study for emrusolmin, an experimental drug. The decision followed an interim futility review. H.C. Wainwright initiated coverage with a Buy rating and $52 price target, citing growth in existing brands. The broader market advanced, with Teva's underperformance attributed to company-specific news.

Original reporting
investing.com
Published Nov 2, 2026, 2:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 3:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TEVA
Bearish
high confidence
Mentioned
$TEVA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TEVABearishMed
01

Why it matters

The independent data monitoring committee recommended halting the trial after interim analysis met a futility criterion, leading Teva to discontinue the study. The article also notes no safety concerns and that this is not a final decision on the broader emrusolmin program.

02

Market read

A direct clinical-trial setback is removing a near-term catalyst, but the lack of safety issues and upcoming earnings keep the stock’s path dependent on near-term financial updates.

03

What to watch

The stock’s reaction may be amplified by positioning ahead of the Nov 3 earnings date; guidance and cash allocation for the broader emrusolmin program could quickly change the narrative.

Relevance 7/10Novelty 8/10Timing: today’s pre-earnings session, with next earnings scheduled for Nov 3, 2026

Background

Teva is evaluating emrusolmin (TEV-’286) in multiple system atrophy via the Phase 2 TOPAS-MSA study.

Company-level read

Ticker impact

$TEVABearishHigh confidence
Context

Teva shares slid after it announced it will discontinue its Phase 2 TOPAS-MSA study of emrusolmin (TEV-’286) following an interim futility review.

Expected impact

Likely continued downside pressure or elevated volatility as investors reprice the emrusolmin development outlook, partially offset by the lack of safety concerns and analyst coverage.

Evidence & confidence

The article cites a prespecified interim futility criterion met by an independent committee, which is a direct negative for efficacy expectations, while explicitly stating no safety issues and that the broader program decision is not final.

Market effects

Sector

Adds to biotech sentiment around clinical-trial risk and the market’s sensitivity to interim futility outcomes.

Regional

Limited spillover expected since the article attributes weakness to company-specific developments.

Global

Primarily impacts Teva and rare neurodegeneration drug development sentiment rather than global pharma flows.

Counterpoint

What could challenge this read

Investors may treat the discontinuation as a capital-efficiency decision rather than a fundamental blow to Teva’s overall turnaround, especially given the article’s emphasis on no safety concerns and existing-brand profitability.

Key entities

  • company
    Teva Pharma Industries Ltd

    Subject of the article; discontinued Phase 2 TOPAS-MSA study of emrusolmin after interim futility review.

  • analyst_firm
    H.C. Wainwright

    Initiated coverage with a Buy rating and a $52 price target, partially offsetting the selloff.

  • clinical_trial_entity
    Independent data monitoring committee

    Recommended halting the trial based on prespecified interim futility criteria.

Read at source← All news

Related articles

NOV 3
$TEVAMed

Teva Pharmaceutical Industries Ltd: Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Teva Pharmaceutical and Samsung Bioepis agreed to commercialize two FDA-approved biosimilars in the U.S. Teva will obtain rights to ETICOVO upon close and infliximab-abda in Q3 2027. The deal expands Teva's biosimilars portfolio as part of its Pivot to Growth strategy. Samsung Bioepis will retain regulatory and manufacturing responsibilities. Financial terms include an upfront payment and potential milestone payments.

finanznachrichten.de2 min
NOV 3
$TEVAMed

Teva signs deal for two FDA-approved biosimilars

Teva Pharmaceutical (TEVA) signed a deal with Samsung Bioepis to commercialize two FDA-approved biosimilars, ETICOVO and infliximab-abda, in the U.S. Teva will gain rights to ETICOVO at closing and infliximab-abda in Q3 2027, with the transaction expected to close by late 2026. Teva will make payments over three years and potentially additional milestone payments.

grafa.com2 min
NOV 3
$TEVAMed

Teva to halt Phase II MSA therapy trial after futility analysis

Teva Pharmaceuticals halted a Phase II trial for emrusolmin (TEV-‘286) to treat multiple system atrophy (MSA) after an interim analysis suggested it would not meet its primary efficacy endpoint. The decision followed a recommendation from the independent data monitoring committee (IDMC), which found a low probability of demonstrating efficacy. No safety concerns were raised. Teva is developing the therapy in collaboration with privately managed biotechnology company MODAG.

clinicaltrialsarena.com4 min
NOV 3
$TEVAMed

Samsung Bioepis teams with Teva to sell two US biosimilars

Samsung Bioepis (0126Z0) and Teva Pharmaceuticals agreed to commercialize two biosimilars in the U.S. Samsung Bioepis will handle development and supply, while Teva manages sales. The deal is valued at up to $420 million, including upfront and milestone payments. The biosimilars, Renflexis and Eticovo, treat autoimmune diseases and have FDA approval.

biz.chosun.com2 min